Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03960424 · ClinicalTrials.gov registry record · NA
Diabetes Management Program for Hispanic/Latino
A NA study, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
NCT03960424: Completed NA study, sponsored by Northwell Health.
NCT03960424 is a NA study that has completed, run by Northwell Health. The registered enrollment target is 240 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03960424, a NA study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
Study Summary
To compare Diabetes Telemonitoring to comprehensive outpatient management (COM) on critical patient-centered outcomes, including HbA1c.
Primary Outcome
HbA1c
Interventions
- OTHER Comprehensive Outpatient Management
- BEHAVIORAL Diabetes Telemonitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2023-09-08 |
| Phase | NA |
What the finished NCT03960424 record still lists
NCT03960424 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Comprehensive Outpatient Management is the first listed.
NCT03960424 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03960424 about?
NCT03960424 is a clinical study titled "Diabetes Management Program for Hispanic/Latino". To compare Diabetes Telemonitoring to comprehensive outpatient management (COM) on critical patient-centered outcomes, including HbA1c.
What is the current status of trial NCT03960424?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2019-09-30. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT03960424?
The interventions under investigation include: Comprehensive Outpatient Management (OTHER), Diabetes Telemonitoring (BEHAVIORAL).
Who is sponsoring clinical trial NCT03960424?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03960424's enrollment target sits among peer trials
240 440th of 2000 higher than 1,542 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI